Spero therapeutics to report first quarter 2025 financial results and provide business update on tuesday, may 13, 2025

Cambridge, mass., may 05, 2025 (globe newswire) -- spero therapeutics , inc. (nasdaq: spro), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on tuesday, may 13, after the market close.
SPRO Ratings Summary
SPRO Quant Ranking